CAMBRIDGE, Mass.– Valink Therapeutics Inc., a private biotechnology company developing next-generation oncology therapeutics focused on bispecific antibody-drug conjugates (bsADCs) and complementary treatment modalities, announced it has closed an $11.8 million pre-A financing round and expanded its U.S. presence with new headquarters in Cambridge, Massachusetts.
The funding will accelerate the advancement of Valink’s pipeline of first-in-class therapeutics designed to improve the efficacy, safety, and precision of cancer treatment.
“We are grateful to redalpine and our syndicate of new and existing investors for their confidence in our vision and strategy,” said Arne Scheu, DPhil, Co-founder and Chief Executive Officer of Valink Therapeutics. “This financing strengthens our position as a leader in next-generation bispecific ADCs and supports the advancement of our oncology pipeline toward key milestones. Our V-gate approach and proprietary discovery engine expand the frontier of antibody-drug conjugates, offering the potential for first-in-class medicines to address areas of high unmet need in oncology and beyond.”
Valink’s bsADC platform is designed to overcome key limitations of conventional ADCs by integrating novel targeting strategies with improved payload delivery. The company is also developing complementary therapeutic modalities to expand its reach across multiple cancer indications.
The round was led by European venture capital fund redalpine, with participation from new investors LongeVC and Oxford Science Enterprises. Existing investors, including RV Invest, p53 Invest, and Hoxton Ventures, also joined the financing.
“At redalpine, we back technologies that reshape paradigms,” said Michael Sidler, founding partner of redalpine and member of Valink’s board of directors. “Valink’s discovery platform and V-gate approach represent a compelling advancement over traditional ADC strategies—unlocking new therapeutic possibilities by combining programmable biology with a novel framework for target synergy. We’re excited to lead this round and support Valink’s mission to address real-world disease biology with precision and adaptability.”
